Introduction Hypertrophic cardiomyopathy (HCM) is a myocardial disease, usually of genetic origin, characterized by increased left ventricular wall thickness unexplained by abnormal loading conditions. Dynamic left ventricular outflow tract (LVOT) obstruction occurs in approximately 70% of patients, either at rest or with provocation, and is closely associated with symptoms and adverse clinical outcomes., The relief of the obstructive gradient remains a major therapeutic goal in obstructive HCM. Mavacamten, a cardiac myosin inhibitor, has been shown to reduce LVOT gradients and […]